AbbVie Inc. (NYSE:ABBV)‘s stock had its “hold” rating reaffirmed by research analysts at Leerink Swann in a research report issued on Tuesday.

The analysts wrote, “Leerink Swann Reiterates a Hold Rating on AbbVie | Analyst Ratings

window._wpemojiSettings = {“baseUrl”:”https:\/\/s.w.org\/images\/core\/emoji\/72×72\/”,”ext”:”.png”,”source”:{“concatemoji”:”http:\/\/www.analystratings.com\/wp-includes\/js\/wp-emoji-release.min.js?ver=4.5.4″}};
!function(a,b,c){function d(a){var c,d,e,f=b.createElement(“canvas”),g=f.getContext&&f.getContext(“2d”),h=String.fromCharCode;if(!g||!g.fillText)return!1;switch(g.textBaseline=”top”,g.font=”600 32px Arial”,a){case”flag”:return g.fillText(h(55356,56806,55356,56826),0,0),f.toDataURL().length>3e3;case”diversity”:return g.fillText(h(55356,57221),0,0),c=g.getImageData(16,16,1,1).data,d=c[0]+”,”+c[1]+”,”+c[2]+”,”+c[3],g.fillText(h(55356,57221,55356,57343),0,0),c=g.getImageData(16,16,1,1).data,e=c[0]+”,”+c[1]+”,”+c[2]+”,”+c[3],d!==e;case”simple”:return g.fillText(h(55357,56835),0,0),0!==g.getImageData(16,16,1,1).data[0];case”unicode8″:return g.fillText(h(55356,57135),0,0),0!==g.getImageData(16,16,1,1).data[0]}return!1}function e(a){var c=b.createElement(“script”);c.src=a,c.type=”text/javascript”,b.getElementsByTagName(“head”)[0].appendChild(c)}var f,g,h,i;for(i=Array(“simple”,”flag”,”unicode8″,”diversity”),c.supports={everything:!0,everythingExceptFlag:!0},h=0;h

var sampling_active = 0;
var sampling_rate = 100;
var do_request = false;

if ( !sampling_active ) {
do_request = true;
} else {
var num = Math.floor(Math.random() * sampling_rate) + 1;
do_request = ( 1 === num );
}

if ( do_request ) {

/* Create XMLHttpRequest object and set variables */
var xhr = ( window.XMLHttpRequest )
? new XMLHttpRequest()
: new ActiveXObject( “Microsoft.XMLHTTP” ),
url = ‘https://www.analystratings.com/wp-admin/admin-ajax.php’,
params = ‘action=update_views_ajax&token=79dde734e8&wpp_id=459175’;
/* Set request method and target URL */
xhr.open( “POST”, url, true );
/* Set request header */
xhr.setRequestHeader( “Content-type”, “application/x-www-form-urlencoded” );
/* Hook into onreadystatechange */
xhr.onreadystatechange = function() {
if ( 4 === xhr.readyState && 200 === xhr.status ) {
if ( window.console && window.console.log ) {
window.console.log( xhr.responseText );
}
}
};
/* Send request */
xhr.send( params );

}

(function(i,s,o,g,r,a,m){i[‘GoogleAnalyticsObject’]=r;i[r]=i[r]||function(){
(i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
})(window,document,’script’,’//www.google-analytics.com/analytics.js’,’ga’);
ga(‘create’, ‘UA-55014446-1’, ‘auto’);
ga(‘send’, ‘pageview’);

window.$ = jQuery;

–>

Stock Market
Best Performing Analysts
Sectors

Basic Materials
Consumer Goods
Financial
Healthcare
Industrial Goods
Services
Technology
Utilities

Most Popular
Contact Us

Home » Leerink Swann Reiterates a Hold Rating on AbbVie”

Several other brokerages have also recently weighed in on ABBV. BMO Capital Markets restated a “market perform” rating and issued a $63.00 price target on shares of AbbVie in a research report on Tuesday. Citigroup Inc. restated a “buy” rating on shares of AbbVie in a research report on Tuesday. Jefferies Group restated a “buy” rating and issued a $90.00 price target on shares of AbbVie in a research report on Tuesday, November 1st. Credit Suisse Group AG cut shares of AbbVie from an “outperform” rating to a “neutral” rating and reduced their price target for the stock from $70.00 to $60.00 in a research report on Monday, October 31st. Finally, Zacks Investment Research upgraded shares of AbbVie from a “hold” rating to a “buy” rating and set a $72.00 price target on the stock in a research report on Wednesday, September 28th. One equities research analyst has rated the stock with a sell rating, nine have issued a hold rating and eight have given a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus price target of $69.83.

Analyst Recommendations for AbbVie (NYSE:ABBV)

Shares of AbbVie (NYSE:ABBV) opened at 62.64 on Tuesday. AbbVie has a 12 month low of $50.71 and a 12 month high of $68.12. The stock has a market cap of $102.01 billion, a PE ratio of 16.93 and a beta of 1.55. The firm’s 50-day moving average is $61.29 and its 200 day moving average is $62.74.

AbbVie (NYSE:ABBV) last issued its quarterly earnings results on Friday, October 28th. The company reported $1.21 earnings per share for the quarter, beating the consensus estimate of $1.20 by $0.01. AbbVie had a net margin of 24.08% and a return on equity of 164.49%. The business had revenue of $6.43 billion for the quarter, compared to the consensus estimate of $6.55 billion. During the same quarter in the previous year, the firm earned $1.13 earnings per share. The company’s revenue for the quarter was up 7.4% on a year-over-year basis. On average, equities analysts predict that AbbVie will post $4.82 EPS for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, February 15th. Investors of record on Friday, January 13th will be issued a $0.64 dividend. This represents a $2.56 annualized dividend and a yield of 4.09%. The ex-dividend date of this dividend is Wednesday, January 11th. This is an increase from AbbVie’s previous quarterly dividend of $0.57. AbbVie’s dividend payout ratio is 61.62%.

In related news, insider Laura J. Schumacher sold 50,000 shares of the stock in a transaction that occurred on Wednesday, September 7th. The shares were sold at an average price of $65.00, for a total value of $3,250,000.00. Following the transaction, the insider now owns 144,138 shares in the company, valued at approximately $9,368,970. The sale was disclosed in a filing with the SEC, which is available through this link. 0.11% of the stock is currently owned by corporate insiders.

A number of institutional investors have recently modified their holdings of ABBV. Suntrust Banks Inc. raised its stake in AbbVie by 8.5% in the third quarter. Suntrust Banks Inc. now owns 1,200,489 shares of the company’s stock valued at $75,713,000 after buying an additional 94,219 shares in the last quarter. American International Group Inc. raised its stake in AbbVie by 0.4% in the third quarter. American International Group Inc. now owns 701,130 shares of the company’s stock valued at $44,220,000 after buying an additional 3,096 shares in the last quarter. Tiedemann Wealth Management LLC bought a new stake in AbbVie during the third quarter valued at approximately $572,000. Jaffetilchin Investment Partners LLC raised its stake in AbbVie by 11.1% in the third quarter. Jaffetilchin Investment Partners LLC now owns 14,820 shares of the company’s stock valued at $935,000 after buying an additional 1,478 shares in the last quarter. Finally, Geneva Advisors LLC raised its stake in AbbVie by 13.3% in the third quarter. Geneva Advisors LLC now owns 86,242 shares of the company’s stock valued at $5,439,000 after buying an additional 10,122 shares in the last quarter. Institutional investors own 68.51% of the company’s stock.

About AbbVie

AbbVie Inc (AbbVie) is a research-based biopharmaceutical company. The Company develops and markets therapies that address a range of diseases. The Company operates in pharmaceutical products segment. Its products are focused on treating conditions, such as chronic autoimmune diseases, in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, as well as other serious health conditions.

5 Day Chart for NYSE:ABBV

Receive News & Stock Ratings for AbbVie Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie Inc. and related stocks with our FREE daily email newsletter.